Seroatlas · Human Serome Atlas

HLA-DRA

HLA class II histocompatibility antigen, DR alpha chain

Also known as: DRA_HUMAN, HLA-DRA1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01903
Gene
HLA-DRA
Ensembl
ENSG00000204287
Chromosome
6
Canonical length
254 aa
Protein class
Plasma proteins, Predicted membrane proteins

OverviewNCBI Gene

HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. This molecule is expressed on the surface of various antigen presenting cells such as B lymphocytes, dendritic cells, and monocytes/macrophages, and plays a central role in the immune system and response by presenting peptides derived from extracellular proteins, in particular, pathogen-derived peptides to T cells. The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Aug 2020]

Canonical amino-acid sequenceUniProt

254 residues, UniProt reviewed canonical sequence.

>P01903|HLA-DRA
     1  MAISGVPVLG FFIIAVLMSA QESWAIKEEH VIIQAEFYLN PDQSGEFMFD FDGDEIFHVD
    61  MAKKETVWRL EEFGRFASFE AQGALANIAV DKANLEIMTK RSNYTPITNV PPEVTVLTNS
   121  PVELREPNVL ICFIDKFTPP VVNVTWLRNG KPVTTGVSET VFLPREDHLF RKFHYLPFLP
   181  STEDVYDCRV EHWGLDEPLL KHWEFDAPSP LPETTENVVC ALGLTVGLVG IIIGTIFIIK
   241  GLRKSNAAER RGPL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against HLA-DRA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
1,197 nTPM

Expression across tissuesHPA

Tissue

  • lymph node: 1,197 nTPM
  • spleen: 1,077 nTPM
  • lung: 931 nTPM
  • tonsil: 754 nTPM
  • small intestine: 700 nTPM
  • adipose tissue: 509 nTPM

Single-cell type

  • cdc: 2,677 nCPM
  • macrophages: 502 nCPM
  • microglia: 439 nCPM
  • endometrial secretory cells: 417 nCPM
  • monocytes: 371 nCPM
  • kupffer cells: 367 nCPM

Immune cell

  • naive B-cell: 420 nTPM
  • intermediate monocyte: 409 nTPM
  • memory B-cell: 380 nTPM
  • non-classical monocyte: 255 nTPM
  • plasmacytoid DC: 231 nTPM
  • classical monocyte: 210 nTPM

Brain region

  • midbrain: 11 nTPM
  • medulla oblongata: 7.4 nTPM
  • white matter: 4.9 nTPM
  • pons: 4 nTPM
  • thalamus: 2.2 nTPM
  • basal ganglia: 2 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about HLA-DRA.

Disease | ImmuneIEDB

Conditions an epitope on HLA-DRA was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.59
gnomAD pLI
0.52
gnomAD missense Z
1.17
DepMap mean gene effect
0.08
DepMap dependency class
selective

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of HLA-DRA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads HLA-DRA as an antibody target. Whether an autoantibody or antibody against HLA-DRA could matter depends on whether native HLA-DRA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

HLA-DRA is annotated at the cell surface, where native HLA-DRA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label HLA-DRA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/HLA-DRA. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...